NeuroSense Therapeutics Ltd. financial data

Symbol
NRSN, NRSNW on Nasdaq
Industry
Pharmaceutical Preparations
Location
11 Hamenofim St., Building B, Herzliya, Israel
State of incorporation
Israel
Fiscal year end
December 31
Latest financial report
6-K - Q4 2023 - Jun 17, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 15.4M shares
Common Stock, Shares, Outstanding 15.4M shares +30.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.64M USD -25.5%
Assets, Current 2.92M USD -60.5%
Property, Plant and Equipment, Net 85K USD +10.4%
Operating Lease, Right-of-Use Asset 162K USD -31.4%
Assets 3.18M USD -58.8%
Employee-related Liabilities, Current 370K USD
Liabilities, Current 3.46M USD +100%
Operating Lease, Liability, Noncurrent 73K USD -50.3%
Liabilities 5.05M USD +142%
Retained Earnings (Accumulated Deficit) -26.1M USD -63.1%
Stockholders' Equity Attributable to Parent -1.76M USD -130%
Liabilities and Equity 3.19M USD -58.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 60M shares 0%
Common Stock, Shares, Issued 15.4M shares +30.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.64M USD -25.5%
Deferred Tax Assets, Valuation Allowance 4.76M USD +128%
Operating Lease, Liability 142K USD
Lessee, Operating Lease, Liability, to be Paid 152K USD
Operating Lease, Liability, Current 69K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 78K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 74K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 10K USD
Deferred Tax Assets, Operating Loss Carryforwards 3.32M USD +101%
Deferred Tax Assets, Net of Valuation Allowance 4.76M USD +128%